Abstract] Human norovirus is the most common cause of acute gastroenteritis worldwide, resulting in estimated mortality of ~210,000 each year, of whom most are children under the age of five. However, norovirus can infect people of all age groups. There is a risk of prolonged infection in children, the elderly and patients who are immunocompromised. To study the inhibition of persistent norovirus replication by small molecule antivirals in vivo, we used a murine norovirus CR6 strain (MNV.CR6). We demonstrated earlier that efficient small molecules can reduce viral shedding in the stool of infected mice. Here we present how to generate the MNV.CR6 virus stock, infect type I and II interferon receptor knockout AG129 mice via oral gavage, administer antivirals to mice, and quantify viral genome copies in the stool of these mice.
[Background] Human noroviruses are an important cause of gastroenteritis. Although most norovirus infections are acute and self-limiting, the infection can become chronic in patients with an immunodeficient status, particularly in solid organ and hematopoietic stem cell transplant recipients, patients undergoing chemotherapy and patients with AIDS (Westhoff et al., 2009; Green, 2014; Angarone et al., 2016) . Prolonged norovirus infection is also observed in young children and the elderly resulting in an increased duration of illness, increased defecations and virus shedding for up to 47 days (Murata et al., 2007; Aoki et al., 2010) . Reduction of immunosuppressive therapy is, when feasible, the strategy of choice to control the infection in transplant recipients. Specific antiviral therapies to treat (chronic) norovirus gastroenteritis are not available. To assess the inhibitory effect of small molecules on persistent norovirus infections, we used a mouse-adapted persistent murine norovirus (MNV.CR6) in type I and II interferon receptor knockout AG129 mice (Strong et al., 2012) . MNV is a genogroup V norovirus that is widely used as a surrogate for human noroviruses, which comprises around 30 strains (Karst et al., 2003; Wobus et al., 2004) . The MNV.CR6 is avirulent in AG129 and STAT1 -/-mice, but replicates for weeks to months in wild type mice and to higher titers in innate immune-deficient mice (Thackray et al., 2007) . The MNV.CR6 strain has a tropism for the proximal colon and the cecum, where it persists and replicates more efficiently than the MNV.CW3 strain, which causes acute infection (Arias et al., 2012; Nice et al., 2013 1. Split the RAW264.7 cells using a cell scraper, once a week at a 1:10 ratio in a T150 flask containing 40 ml of 10% media. Maintain the cells in a CO2 incubator at 5% CO2 and 37 °C. c. Add 20 ml of 2% media and place the flask back in the incubator until the full cytopathic effect is observed (± 2-3 days post-infection).
3. Repeat two freeze-thaw cycles (-80 °C vs. 37 °C), then collect the supernatants containing the virus after centrifugation (10 min, 1,500 x g) and store in aliquots (500-1,000 µl) in cryotubes at -80 °C.
4. Determine the viral titer by endpoint titration as previously described in Reed et al. (1938) . This procedure is based on the detection of cytopathic effect (CPE) by microscopy.
Note: Titration can be performed with a higher dilution series or extended over a second 96-well
plate when the viral stock is strong.
a. Thaw MNV.CR6 stock at room temperature.
b. Add 100 µl of 2% DMEM in all wells of a 96-well plate.
c. Add 50 µl of pure virus stock in the wells B2-G2 of the second column of the 96-well plate.
d. Homogenize the virus and medium with a multichannel pipette.
e. Take 50 µl of the mixture and transfer into the next well.
f. Repeat Steps A4d-A4e until reaching column 9 of the 96 well-plate.
g. Homogenize the virus and medium in row 9 and discard 50 µl.
h. Add 10,000 RAW 264.7 cells/well in a final volume of 100 µl in 2% DMEM, to the inner 60 wells.
i. Incubate for 72 h in 5% CO2 at 37 °C.
j. Compare the wells with infected cells (columns 2-9) to the wells with non-infected cells (columns 10-11) and evaluate for cytopathic effect (CPE) microscopically.
k. Calculate TCID50 using the Reed-Muench formula (Reed et al., 1938 1. Tag an ear of each mouse with a unique number.
2. Thaw virus and dilute in 2% media to 10 6 CCID50 (50% cell culture infectious dose) of MNV.CR6.
Give each mouse 200 μl of virus via oral gavage (see below).
3. Fill the syringe and feeding tube with virus and remove all air bubbles.
4. Carefully pick up the mouse by the base of its tail, place onto a wire cage.
5. With the other hand, restrain the mouse by holding the scruff between thumb and forefinger.
Place the tail between the little finger and ring finger to stretch the mouse (Figure 1 ). 2. Place each mouse individually in a clean plastic container awaiting the defecation.
3. Use a forceps to collect one piece of feces and place it in a labeled 1.5 ml tube (Figure 4 ).
Repeat for all mice.
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